Results 61 to 70 of about 50,656 (201)

The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs [PDF]

, 2013
G protein coupled receptors (GPCRs) are the most historically successful therapeutic targets. Despite this success there are many important aspects of GPCR pharmacology and function that have yet to be exploited to their full therapeutic potential.
Hudson, Brian D., Milligan, Graeme, Ulven, Trond   +2 more
core   +1 more source

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update [PDF]

Endocrinology and Metabolism
Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide. In the last 20 years, the emergence of pharmacological treatments for obesity based on gastrointestinal hormones has transformed the therapeutic ...
Agnieszka Jakubowska, Carel W. le Roux, Adie Viljoen   +2 more
doaj   +1 more source

Metabolic Syndrome Abolishes Glucagon-Like Peptide 1 Receptor Agonist Stimulation of SERCA in Coronary Smooth Muscle [PDF]

, 2015
Metabolic syndrome (MetS) doubles the risk of adverse cardiovascular events. Glucagon-like peptide 1 (GLP-1) receptor agonists induce weight loss, increase insulin secretion, and improve glucose tolerance.
Alloosh, Mouhamad, Bell, Lauren N., Chalasani, Naga, Dineen, Stacey L., Fullenkamp, Allison M., McKenney, Mikaela L., Schultz, Kyle A., Sturek, Michael   +7 more
core   +1 more source

Small-molecule agonists for the glucagon-like peptide 1 receptor [PDF]

Proceedings of the National Academy of Sciences, 2007
The peptide hormone glucagon-like peptide (GLP)-1 has important actions resulting in glucose lowering along with weight loss in patients with type 2 diabetes. As a peptide hormone, GLP-1 has to be administered by injection. Only a few small-molecule agonists to peptide hormone receptors have been described and none in the B family of the G protein ...
Knudsen, Lotte Bjerre, Kiel, Dan, Teng, Min, Behrens, Carsten, Bhumralkar, Dilip, Kodra, János T, Holst, Jens Juul, Jeppesen, Claus B, Johnson, Michael D, de Jong, Johannes Cornelis, Jorgensen, Anker Steen, Kercher, Tim, Kostrowicki, Jarek, Madsen, Peter, Olesen, Preben H, Petersen, Jacob S, Poulsen, Fritz, Sidelmann, Ulla G, Sturis, Jeppe, Truesdale, Larry, May, John, Lau, Jesper   +21 more
openaire   +3 more sources

Diffuse Podocytopathy Associated With Semaglutide

Annals of Internal Medicine: Clinical Cases
We present 3 cases of biopsy-proven minimal change disease occurring in close temporal association with semaglutide (glucagon-like peptide 1 receptor agonists) exposure.
Rose Mary Attieh, Grant Kirby, Yang Yihe, Serena Bagnasco, Andrew A. Moses, Mahmoud Abdelaziz, Rimda Wanchoo, Samir Gautam, Astrid Weins, Kenar D. Jhaveri   +9 more
doaj   +1 more source

Microbiota-Produced N-Formyl Peptide fMLF Promotes Obesity-Induced Glucose Intolerance. [PDF]

, 2019
The composition of the gastrointestinal microbiota and associated metabolites changes dramatically with diet and the development of obesity. Although many correlations have been described, specific mechanistic links between these changes and glucose ...
Chan, Luisa S, Chordia, Mahendra D, El Ouarrat, Dalila, Han, Andrew W, Jain, Mohit, Johnson, Andrew MF, Lee, Yun Sok, Mahmood, Nadir A, Ofrecio, Jachelle M, Olefsky, Jerrold M, Pan, Dongfeng, Riopel, Matthew, Ryan, Caitlin N, Watrous, Jeramie D, Wollam, Joshua, Xu, Yong-Jiang, Ying, Wei   +16 more
core   +1 more source

Central mechanisms mediating the hypophagic effects of oleoylethanolamide and N-acylphosphatidylethanolamines: different lipid signals? [PDF]

, 2015
The spread of "obesity epidemic" and the poor efficacy of many anti-obesity therapies in the long-term highlight the need to develop novel efficacious therapy. This necessity stimulates a large research effort to find novel mechanisms controlling feeding
Gaetani, Silvana, Passani, Maria B., Provensi, Gustavo, Romano, Adele, Tempesta, Bianca   +4 more
core   +2 more sources

Hydrocarbon-Stitched Peptide Agonists of Glucagon-Like Peptide-1 Receptor

ACS Chemical Biology, 2020
Glucagon-like peptide 1 (GLP-1) is a natural peptide agonist of the GLP-1 receptor (GLP-1R) found on pancreatic β-cells. Engagement of the receptor stimulates insulin release in a glucose-dependent fashion and increases β-cell mass, two ideal features for pharmacologic management of type 2 diabetes.
Gregory H. Bird, Accalia Fu, Silvia Escudero, Marina Godes, Kwadwo Opoku-Nsiah, Thomas E. Wales, Michael D. Cameron, John R. Engen, Nika N. Danial, Loren D. Walensky   +9 more
openaire   +3 more sources

Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning [PDF]

, 2016
This work was supported by the British Heart Foundation (Ref: RG/14/4/30736), Medical Research Council (MR/N02589X/1) and The Wellcome Trust (Ref: 200893/Z/16/Z). A.V.G. is a Wellcome Trust Senior Research Fellow. S.M.
Aleksander Mrochek, Alexander V. Gourine, Ana Gutierrez del Arroyo, Andrey Gourine, Barragán, Gareth L. Ackland, Gourine, Göke, Jenifer Sanchez, John Pernow, Marina V. Basalay, Per-Ove Sjoquist, Svetlana Mastitskaya, Uitterdijk   +13 more
core   +2 more sources

Renoprotective mechanisms of glucagon-like peptide-1 receptor agonists

Diabetes & Metabolism
Glucagon-like peptide-1 (GLP-1) is an incretin hormone, secreted from gut endocrine cells, which acts to potentiate nutrient-induced insulin secretion. Activation of its receptor, GLP-1R, decreases glucagon secretion and gastric emptying, thereby decreasing blood glucose and body weight. It is largely through these mechanisms that Glucagon-like peptide-
Chen J, Cooper ME, Coughlan MT
openaire   +2 more sources